Alkermes plc · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · Ireland
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-02$34.96 RISE2026-03-18$27.20 PEAK2026-05-29$42.19 116d | -22.2% 44d | Missed | Missed | — | — | +55.1% 72d | Missed |
DROP2025-11-11$33.81 RISE2025-12-30$27.81 PEAK2026-02-02$34.96 83d | -17.7% 49d | Missed | Missed | — | — | +25.7% 34d | Missed |
DROP2025-11-11$33.81 RISE2025-12-18$27.81 PEAK2026-02-02$34.96 83d | -17.7% 37d | Missed | Missed | — | — | +25.7% 46d | Missed |
DROP2025-06-06$31.71 RISE2025-09-15$26.52 PEAK2025-11-11$33.81 158d | -16.4% 101d | Missed | Missed | — | — | +27.5% 57d | Missed |
DROP2025-03-24$34.79 RISE2025-07-25$26.13 PEAK2025-10-15$32.23 205d | -24.9% 123d | Missed | Missed | — | — | +23.3% 82d | Missed |
DROP2025-02-13$36.00 RISE2025-04-10$26.59 PEAK2025-05-02$31.78 78d | -26.1% 56d | Missed | Missed | — | — | +19.5% 22d | Missed |
DROP2024-03-01$30.24 RISE2024-07-10$23.01 PEAK2024-10-02$29.00 215d | -23.9% 131d | Missed | Missed | — | — | +26.0% 84d | Missed |
DROP2024-02-15$32.56 RISE2024-05-30$23.21 PEAK2024-08-26$28.51 193d | -28.7% 105d | Missed | Missed | — | — | +22.8% 88d | Missed |
DROP2023-07-20$31.97 RISE2023-11-16$23.37 PEAK2024-01-08$29.60 172d | -26.9% 119d | Missed | Missed | — | — | +26.7% 53d | Missed |
DROP2022-07-06$31.87 RISE2022-10-10$21.94 PEAK2022-12-29$26.24 176d | -31.2% 96d | Missed | Missed | — | — | +19.6% 80d | Missed |
DROP2021-10-07$32.08 RISE2022-02-14$23.07 PEAK2022-04-27$30.38 202d | -28.1% 130d | Missed | Missed | — | — | +31.7% 72d | Missed |
DROP2021-09-28$32.13 RISE2021-12-01$21.47 PEAK2022-02-16$26.79 141d | -33.2% 64d | Missed | Missed | — | — | +24.8% 77d | Missed |
DROP2021-02-09$23.20 RISE2021-03-04$18.21 PEAK2021-05-28$22.67 108d | -21.5% 23d | Missed | Missed | — | — | +24.5% 85d | Missed |
DROP2020-07-27$20.66 RISE2020-10-28$15.39 PEAK2021-01-25$22.87 182d | -25.5% 93d | Missed | Missed | — | — | +48.6% 89d | Missed |
DROP2020-03-02$21.24 RISE2020-05-01$13.31 PEAK2020-07-27$20.66 147d | -37.3% 60d | Missed | Missed | — | — | +55.2% 87d | Missed |
1–15 / 16 1 / 2 | |||||||
Shareholders appeared unconcerned with Alkermes plc's ( NASDAQ:ALKS ) lackluster earnings report last week. We think...
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $45 to $48.
Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Stre
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.1% and the State S
Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as analysts raised price targets.
Alkermes plc announced positive topline results from the REVITALYZ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ ...
Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of
Alkermes Plc: Alkermes announces positive topline results from Revitalyz phase 3 study evaluating Lumryz® extended-release in adults with idiopathic hypersomnia Alkermes Plc - Lumryz meets all...
– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and...
2026-05-07. The following slide deck was published by Alkermes plc in conjunction with their 2026 Q1 earnings call.
UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $42 to $48.
Alkermes' (ALKS) better-than-expected Q1 revenue highlights the "underappreciated nature" of the com
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
Alkermes reports positive Q1 results, beating expectations. Raises EPS guidance and maintains sales guidance. Analysts raise price targets.
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $43 to $44.
Alkermes is transitioning into an integrated neuroscience and sleep medicine company. Click here to see why ALKS stock is a Buy.
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $45 to $50.
Moby summary of Alkermes plc's Q1 2026 earnings call
During the quarter, we closed the acquisition of Avadel Pharmaceuticals plc. The financial results announced today reflect the mid-February closing of the transaction and the integration of Avadel into our business, including 6 weeks of contribution from LUMRYZ, Avadel's once-at-bedtime sodium oxybate for the treatment of narcolepsy. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation, our press release issued this morning and our most recent annual report filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements.
Alkermes plc (ALKS) Q1 2026 Earnings Call May 5, 2026 8:00 AM EDTCompany ParticipantsSandra Coombs - Senior Vice President of Corporate Affairs &...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALKS | +26.39% | +39.47% | +50.79% | +37.83% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +23.42% | +45.19% | +54.23% | +25.14% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 9.47M | $334.69M | 0.01% | Unchanged | 2026-03-31 |
| RenTech | quant | 6.16M | $217.83M | 0.34% | Trimmed-7.6% | 2026-03-31 |
| Wellington | fundamental | 2.97M | $105.03M | 0.02% | Trimmed-1.7% | 2026-03-31 |
| FidelityFMR | fundamental | 1.32M | $46.81M | 0.00% | Trimmed-2.3% | 2026-03-31 |
| TwoSigma | quant | 780.7K | $27.60M | 0.02% | Trimmed-35.7% | 2026-03-31 |
| DEShaw | quant | 710.3K | $25.12M | 0.02% | Trimmed-22.1% | 2026-03-31 |
| Bridgewater | macro | 83.8K | $2.96M | 0.01% | Trimmed-75.7% | 2026-03-31 |
| TRowePrice | fundamental | 4.66M | $164.94K | 0.02% | Trimmed-48.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-28upcoming | 0.33 | — | — |
| 2026-05-05 | -0.04 | 0.38 | +1053.00% |
| 2026-02-25 | 0.34 | 0.29 | -15.27% |
| 2025-10-28 | 0.30 | 0.49 | +62.19% |
| 2025-07-29 | 0.40 | 0.68 | +71.14% |
| 2025-05-01 | 0.05 | 0.13 | +145.84% |
| 2025-02-12 | 0.76 | 1.05 | +37.62% |
| 2024-10-24 | 0.71 | 0.73 | +2.43% |
| 2024-07-24 | 0.71 | 0.70 | -0.79% |
| 2024-05-01 | 0.58 | 0.43 | -26.20% |
| 2024-02-15 | 0.46 | 0.22 | -52.04% |
| 2023-10-25 | 0.43 | 0.64 | +50.23% |
| 2023-07-26 | 0.64 | 0.55 | -13.79% |
| 2023-04-26 | -0.01 | 0.01 | +180.00% |
| 2023-02-16 | 0.05 | 0.14 | +210.83% |
| 2022-11-02 | 0.03 | 0.02 | -32.82% |